IRulya Therapeutics Inc.
IRLA Nasdaq
SEC CIK 1662774
Follow IRulya Therapeutics
Weekly email: filings, results
Net income
−$27.7M
−106.4% vs same quarter last year
EPS, diluted
−$2.31
Operating cash flow
−$9.8M
+0.9% vs same quarter last year
Operating income
−$13.1M
+2.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$84M |
| FY24 | −$56.8M |
| FY23 | −$31.4M |
| FY22 | −$51.7M |
| FY21 | −$89.9M |
| FY20 | −$76.8M |
| FY19 | −$37M |
| FY18 | −$12.5M |
| FY17 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$41.8M |
| FY24 | −$32.2M |
| FY23 | −$18.5M |
| FY22 | −$44.2M |
| FY21 | −$63.1M |
| FY20 | −$50.9M |
| FY19 | −$33.3M |
| FY18 | −$11.9M |
| FY17 | - |